Current Projects
Translational Research Projects
The Obesity Paradox In Melanoma
Immune checkpoint blockade (ICB) and BRAF-targeted therapy have significantly extended the life expectancy of melanoma patients. However, despite these treatment successes, a substantial 40-65% of those with metastatic melanoma do not survive beyond five years. Recent research has uncovered a perplexing phenomenon: obese patients receiving ICB and BRAF-targeted therapy show improved survival rates compared to their normal-weight counterparts. This unexpected discovery, known as the "obesity paradox," contradicts the establish thinking regarding obesity. In our research project, we aim to unravel this paradox by investigating how obesity-associated changes affect the efficacy of melanoma treatment.
The Genomic Landscape of In-Transit Melanoma
In-transit melanoma (ITM) metastases are cutaneous or subcutaneous deposits of melanoma cells in the drainage area between the primary tumor and the first regional lymph node. ITM is a distinct clinical entity that can be difficult to treat because the tumors can be multiple and encompass a very large area. The mechanisms underlying ITM metastases are not fully understood. While ITM often occurs in the presence of distant metastasis some patients exhibit only aggressive locoregional disease with delayed or no progression to distant sites. Our lab is looking at the unique mutational landscape of ITM metastases to determine if we can determine the underlying mechanism for this unique clinical behavior and possibly find therapeutic targets.
Clinical Research Projects
The Correlation of Visceral Fat with BRAF/MEK Treatment Responses in Melanoma
The Practice Patterns of Treatment for High and Low Risk Thin Melanomas
Training History and NIH Funding for Surgeons
Affordability of Parenthood as a Resident
Credibility of Medical Social Media Influencers
Porocarcinoma Clinical and Pathologic Characteristics
